Ultragenyx Pharmaceutical’s (RARE) “Buy” Rating Reiterated at HC Wainwright

Ultragenyx Pharmaceutical (NASDAQ:RARE)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $60.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 142.40% from the stock’s current price.

A number of other equities research analysts have also recently commented on the stock. Robert W. Baird dropped their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. TD Cowen cut their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Guggenheim decreased their price objective on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research report on Monday, January 5th. Wells Fargo & Company dropped their target price on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Sixteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $72.29.

Ultragenyx Pharmaceutical Trading Up 2.8%

Shares of NASDAQ RARE opened at $24.75 on Tuesday. The company has a 50 day simple moving average of $28.87 and a two-hundred day simple moving average of $29.98. The stock has a market cap of $2.39 billion, a price-to-earnings ratio of -4.17 and a beta of 0.16. Ultragenyx Pharmaceutical has a 12 month low of $18.41 and a 12 month high of $46.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The company had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period last year, the firm earned ($1.40) EPS. Analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Howard Horn sold 3,081 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78. Following the transaction, the chief financial officer directly owned 95,146 shares in the company, valued at $3,461,411.48. The trade was a 3.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Assetmark Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank grew its holdings in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares during the period. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth about $39,000. Elevation Point Wealth Partners LLC purchased a new position in Ultragenyx Pharmaceutical during the second quarter worth about $55,000. Finally, Smartleaf Asset Management LLC boosted its holdings in Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.